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AbstrACt
Introduction Pregnant women and infants are at risk of 
severe influenza and pertussis infection. Inactivated influenza 
vaccine (IIV) and diphtheria-tetanus-acellular pertussis 
vaccine (dTpa) are recommended during pregnancy to 
protect both mothers and infants. In Australia, uptake is 
not routinely monitored but coverage appears sub-optimal. 
Evidence on the safety of combined antenatal IIV and dTpa is 
fragmented or deficient, and there remain knowledge gaps of 
population-level vaccine effectiveness. We aim to establish a 
large, population-based, multi-jurisdictional cohort of mother-
infant pairs to measure the uptake, safety and effectiveness 
of antenatal IIV and dTpa vaccines in three Australian 
jurisdictions. This is a first step toward assessing the impact 
of antenatal vaccination programmes in Australia, which 
can then inform government policy with respect to future 
strategies in national vaccination programmes.
Methods and analysis ‘Links2HealthierBubs’ is an 
observational, population-based, retrospective cohort 
study established through probabilistic record linkage 
of administrative health data. The cohort includes births 
between 2012 and 2017 (~607 605 mother-infant pairs) in 
jurisdictions with population-level antenatal vaccination and 
health outcome data (Western Australia, Queensland and the 
Northern Territory). Perinatal data will be the reference frame 
to identify the cohort. Jurisdictional vaccination registers 
will identify antenatal vaccination status and the gestational 
timing of vaccination. Information on maternal, fetal and child 
health outcomes will be obtained from hospitalisation and 
emergency department records, notifiable diseases databases, 
developmental anomalies databases, birth and mortality 
registers.
Ethics and dissemination Ethical approval was obtained 
from the Western Australian Department of Health, Curtin 
University, the Menzies School of Health Research, the Royal 
Brisbane and Women’s Hospital, and the West Australian 
Aboriginal Health Ethics Committees. Research findings will be 
disseminated in peer-reviewed journals, at scientific meetings, 
and may be incorporated into communication materials for 
public health agencies and the public.
IntroduCtIon
Pregnant women, as a result of their changed 
immunological status, are particularly suscep-
tible to severe infection. Data from studies 
conducted during influenza pandemics have 
shown pregnant women to be at elevated 
risk of severe influenza infection and its 
complications.1 2 Furthermore, the risk of 
hospitalisation from influenza or pneumonia 
increases progressively throughout the preg-
nancy.3 4 Deaths among pregnant women and 
perinatal mortality in infants born to infected 
strengths and limitations of this study
 ► Record linkage allows the generation of a large, rich 
population-based dataset from multiple sources at 
low cost.
 ► Linked data from three jurisdictions will establish a 
cohort with sufficient sample size to enable the ex-
amination of uncommon or rare outcomes (eg, neo-
natal mortality), the evaluation of antenatal vaccines 
among subgroup populations (eg, infants with risk 
factors such as preterm infants, Aboriginal and/or 
Torres Strait Islander peoples), and allows follow-up 
of mother-infant pairs in the cohort over an extended 
period of time.
 ► Inclusion of a geographically and socioeconomically 
diverse, population-based sample will help to mini-
mise selection bias in the cohort.
 ► Analytic techniques will be employed to minimise 
potential bias from differential health-seeking be-
haviour of vaccinated women.
 ► As a retrospective, observational cohort study us-
ing linked administrative data, vaccination can-
not be randomly assigned; however, it allows 
whole-of-population assessment and maximises 
follow-up of the cohort.
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women during the 2009 H1N1 influenza pandemic high-
lighted the disease risk.5 
Respiratory infections during critical periods of lung 
development and immune maturation are one of the 
most common causes of death in early infancy.6 Infants 
aged 1–5 months, an age when they are ineligible for 
influenza vaccine, have the highest rates of influenza.7 In 
Australia, hospitalisation rates of acute lower respiratory 
infection among Aboriginal and/or Torres Strait Islander 
children are nearly six times that of non-Aboriginal chil-
dren.8 Influenza and pertussis infections account for one 
in every four of these hospital admissions.9
In the absence of a licensed and effective vaccine for 
newborns,5 influenza and pertussis vaccination during preg-
nancy has been recommended as a means to safeguard 
newborns during their first few months of life. Randomised 
controlled trials suggest that maternal immunisation against 
influenza prevents infection in both the mother and their 
infant.10 11 Data from the USA and the UK have shown 
that vaccination during pregnancy can reduce influenza 
by 71% and pertussis by 91% in young infants.12 13 In 2012, 
the WHO released a position paper on influenza vaccina-
tion recommending that pregnant women should have the 
highest priority for countries considering expansion of their 
seasonal influenza vaccination programme.14
Inactivated influenza vaccine (IIV) in pregnancy 
has been a long-standing policy recommendation in 
Australia15 and is offered free of charge funded by the 
government. Following the success of maternal vaccina-
tion to prevent pertussis in early infancy in the UK,12 low 
dose diphtheria-tetanus-acellular pertussis vaccine (dTpa) 
became the second vaccine recommended routinely 
during pregnancy in Australia in April 2015 and funded 
by state and national immunisation programmes.15
Despite the importance to health and significant program-
matic costs, Australia currently lacks a coordinated approach 
to maternal vaccination. Uptake of routinely recommended 
vaccines in pregnancy is suboptimal and not systematically 
monitored.16–19 Pregnancy status is not collected as part of 
the national whole-of-life immunisation register, the Austra-
lian Immunisation Register (AIR), making antenatal immu-
nisation impossible to measure using AIR alone. In Western 
Australia (WA), Queensland (QLD) and the Northern 
Territory (NT), antenatal immunisation status is routinely 
collected via either state-based immunisation registers or 
through perinatal data collections. These collections offer 
the opportunity to conduct high-quality, population-level 
evaluation of the health effects of antenatal vaccination 
programmes in these jurisdictions.
The ‘Links2HealthierBubs’ project is a vital first step 
toward national evaluation of antenatal vaccination 
in Australia. Identification of factors associated with 
under-immunisation will enable more targeted vaccine 
promotion. Study results will inform antenatal vaccine 
programmes and Australian governmental policy. 
Improved antenatal vaccination programme moni-
toring and delivery is essential in reducing influenza and 
pertussis-related illness in pregnant women and infants. 
With the establishment of the AIR in 2016, the analyses 
performed here could be applied to a national dataset 
through AIR linkage in future.
AIMs
The ‘Links2HealthierBubs’ study combines health infor-
mation from multiple sources at an individual-level 
designed to improve our understanding of the risks and 
benefits of antenatal immunisation. We will use existing 
record linkage infrastructure to generate a large cohort 
of pregnancies and establish a population-based moth-
er-infant cohort sufficiently powered to estimate rare or 
uncommon outcomes that have not been possible with 
individual state-based data to date to address three aims 
(figure 1).
Aim 1: Measure the effectiveness of IIV and dtpa against 
laboratory-confirmed infections in pregnant women and their 
infants
Although this is a rapidly growing area of research, there 
remain several gaps in our knowledge of antenatal vacci-
nation (table 1). First, limited data have been published 
evaluating effectiveness against disease severity (such as 
hospitalisation).20–23 Few studies have evaluated the influ-
ence of gestational timing of influenza vaccine adminis-
tration on disease prevention in mothers and infants,24–26 
or the safety and effectiveness of repeat doses, particu-
larly with regard to the currently recommended pertussis 
vaccine that also contain tetanus and diphtheria. The 
interval between influenza vaccination and birth is asso-
ciated with changes in the level of protective antibody 
present in newborns.27 Longer intervals between influ-
enza vaccination and delivery, as well as intervals too 
close to delivery, have been shown to result in lower cord-
blood titres in infants, potentially reducing vaccine effec-
tiveness.27 Although known to influence transplacental 
antibody transfer, few studies have measured the impact 
of these factors on clinical end-points, such as hospital-
isation of mothers and infants with respiratory illness. 
Second, few studies have evaluated the role that ante-
natal vaccination may have on the performance of child-
hood vaccines. Immunological evidence of ‘blunting’ of 
infant responses to pertussis vaccines due to interference 
by maternal antibodies has been observed.28–30 Finally, 
despite the disproportionate burden of respiratory infec-
tions among Aboriginal and/or Torres Strait Islander 
infants, the effectiveness of vaccination in pregnancy 
for this population group has not yet been measured in 
Australia. Such data are important for informing future 
prevention programmes.
This cohort study aims to address these gaps by:
1. Measuring the effectiveness of antenatal IIV and dTpa 
vaccines on laboratory-confirmed influenza and per-
tussis infections among mothers and their infants in 
the first 6 months of life, with subgroup analyses by: (1) 
trimester of vaccination and (2) among infants with 
risk factors for infection (eg, preterm birth, small for 
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gestational age (SGA) and Aboriginal and/or Torres 
Strait Islander infants).
2. Assessing the impact of antenatal pertussis vaccination 
on the effectiveness of other childhood vaccines rou-
tinely offered on the immunisation schedule by com-
paring disease notifications in the first 6 months of life 
in fully vaccinated infants of mothers who did and did 
not receive maternal pertussis vaccination.
Aim 2: Assess the safety of IIV and dtpa given antenatally in 
mothers and infants
A number of studies, including several systematic 
reviews,31–33 have found no evidence that IIV or dTpa 
adversely impacts the fetus; however, there is a dearth 
of postimplementation data evaluating the safety of 
combined administration of IIV and dTpa during 
pregnancy in terms of adverse events for mothers and 
differences in birth outcomes following IIV and dTpa 
vaccination during pregnancy. Large, comprehensive 
datasets are required to compare outcomes such as 
preterm birth, birth weight, SGA, birth defects, stillbirth 
and neonatal death (<1 month of age) between women 
who have received IIV and dTpa during pregnancy and 
unvaccinated pregnant women.16 Furthermore, few 
studies have evaluated the potential health impact of 
antenatal IIV and dTpa administration on the health of 
infants beyond 6 months of age.22 34 35
This cohort study will assess the safety of IIV and dTpa 
vaccination during pregnancy on:
1. Health outcomes in the perinatal period and early 
childhood (up to 5 years), including (but not restricted 
to) preterm birth, birth weight, SGA, birth defects and 
cerebral palsy, stillbirth, and neonatal death (<1 month 
of age).
2. Maternal health, including severe adverse events re-
sulting in hospitalisation or admission to the intensive 
care unit (ICU).
Aim 3: Evaluate antenatal vaccine coverage in Australia
A number of studies have identified predictors of ante-
natal vaccination, including maternal age, pre-existing 
medical conditions and socioeconomic status.36 As vaccine 
coverage in pregnant women is not routinely monitored in 
Australia, the influence of other demographic and health 
factors, including geographic variation, is not well under-
stood. Limited data are available by remoteness, geographic 
area and level of socioeconomic deprivation.17 37 Moreover, 
uptake in Aboriginal and/or Torres Strait Islander mothers 
is poorly defined.17 38 Disparities between Aboriginal and 
non-Aboriginal children in the childhood immunisation 
schedule have shown lower vaccine coverage in the first year 
of life in Aboriginal and/or Torres Strait Islander children 
compared with non-Aboriginal infants as a result of greater 
delay in the receipt of vaccines,39 although these trends may 
not be reflected in the uptake of maternal vaccines.
To address this, the ‘Links2HealthierBubs’ cohort study 
aims to:
1. Identify geographic, sociodemographic (including by 
Aboriginal status) and other risk factors associated with 
uptake of IIV and/or dTpa vaccine during pregnancy.
2. Evaluate trends in vaccine uptake among pregnant 
women in Australia.
Figure 1 Establishment of study cohort using record linkage: Western Australia (WA), Queensland (QLD), and the Northern 
Territory (NT), 2012–2017. *Vaccination records were obtained from state-wide registers in each participating jurisdiction; in WA, 
this register was restricted to pregnant women; in the NT and QLD, these registers included all vaccinations administered to 
individuals in the state. †Developmental anomaly data available in WA and QLD; primary care data available in NT only.
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MEthods And AnAlysIs
study design and setting
‘Links2HealthierBubs’ is an observational, popula-
tion-based cohort study using retrospective data collected 
in administrative health registers from three jurisdictions 
of Australia (WA, QLD and the NT) where antenatal vacci-
nation data are currently available at a population-level 
and can be linked to other health information. Together 
these three jurisdictions account for 33% of Australia’s 
annual birth cohort, of which Aboriginal and/or Torres 
Strait Islander births comprise 8.0%, 8.9% and 35.8% of 
total births in each jurisdiction, respectively (table 2).40 
Infants will be identified through jurisdictional birth or 
perinatal registers. All infants born between 1 January 
2012 and 31 December 2017 and their mothers will be 
included as participants in the study. This time period 
was selected as it includes a baseline period when IIV 
was available and routinely recommended,18 but prior 
to the introduction of funded dTpa (2012–2014) and an 
intervention period following the introduction of dTpa 
in jurisdictions (2015–2017). Within each jurisdiction, 
the cohort of mothers and infants will be linked to vacci-
nation and health data, including emergency department 
presentation, hospital separations, birth records, notifi-
able diseases register and mortality data (table 2). With 
the exception of antenatal vaccination registers, these 
registers are nationally mandated and provide data to the 
Australian Institute of Health and Welfare (AIHW), and 
the quality of data is considered to be high.41 Data from 
developmental anomalies registries and primary care will 
also be obtained in jurisdictions where these are available.
Exposure measurement
Individual-level data on antenatal vaccination will be 
obtained from jurisdictional perinatal data collections 
(QLD: 2015–2017, WA: 2016–2017) and immunisation 
registries (NT: 2012–2017, QLD: 2012–2017, WA: 2012–
2016). These data collections have state-wide coverage of 
Table 1 Summary of project aims and knowledge gaps addressed by the Links2HealthierBubs cohort study
Knowledge gap Component of the Study
AIM 1: Vaccine effectiveness
Few studies have measured the effectiveness of antenatal 
influenza and pertussis vaccines in preventing maternal and 
infant laboratory-confirmed infection
Measure effectiveness of antenatal IIV and dTpa on laboratory-
confirmed infection in mothers and in the first 6 months of life 
in infants
There is limited evidence evaluating whether antenatal 
vaccination protects against severe disease in mothers and 
infants
Measure effectiveness against hospitalised infection and 
infections required admission to intensive care unit
Few studies have been sufficiently powered to assess the 
potential influence of gestational timing of vaccination on 
vaccine effectiveness
Assess the potential influence of trimester of the effectiveness 
of vaccination
No studies have measured the effectiveness of antenatal 
vaccination among infants with risk factors for severe disease
Measure effectiveness among infants with risk factors for 
infection (ie, preterm infants, Indigenous infants, infants with 
developmental anomalies)
Despite clinical evidence suggesting the presence of maternal 
antibodies may inhibit infant response to primary pertussis 
vaccination, population-level data evaluating this are limited
Assess the potential influence of maternal pertussis 
immunisation on childhood vaccine effectiveness
AIM 2: Vaccine safety
Limited data exist evaluating the impact of concomitant 
administration of influenza and pertussis vaccines
Assess the safety of IIV and dTpa on maternal and infant 
health
Few studies have been sufficiently powered to assess safety 
end-points by trimester of vaccination
Consider the trimester of vaccination in the assessment of 
safety end-points for IIV and dTpa
Few studies have evaluated outcome measures associated 
with antenatal vaccination beyond 6 months of age
Assess the impact of IIV and dTpa in terms of neonatal, infant 
and child health up to 5 years of age
AIM 3: Vaccine coverage
There are limited data on antenatal uptake of vaccines across 
multiple jurisdictions in Australia including sub-analyses based 
on sociodemographic factors
Estimate the uptake of IIV and dTpa; IIV only and dTpa only in 
the three jurisdictions and special population groups (ie, low-
income, remote, CALD, by maternal country of birth)
Few longitudinal studies exist which have evaluated trends in 
vaccine coverage in multiple Australian jurisdictions
Assess trends in vaccine coverage in multiple Australian 
jurisdictions using population-level data for both IIV and dTpa
No study in Australia has assessed the importance of 
residence or performed spatial analyses in relation to maternal 
vaccination
Identify whether there are geographic, regional, and other 
sociodemographic predictors of vaccination during pregnancy
CALD: culturally and linguistically diverse; dTpa; diphtheria-tetanus-acellular pertussis vaccine; IIV; inactivated influenza vaccine.
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pregnant women and will be used to provide information 
on IIV and dTpa vaccines administered during pregnancy 
and either (1) the gestation of the woman at vaccination, 
or (2) the date of vaccination, which will be used together 
with gestational age and date of birth to extrapolate gesta-
tional age at time of vaccination.
In NT and QLD, where there are immunisation regis-
ters covering the study period, information on childhood 
vaccines will also be obtained, including the vaccine 
administered and the date of administration. Whole-of-
life immunisation data were not available for linkage in 
WA.
outcome measurement
Pregnancy and birth outcomes
Information on the pregnancy, labour and birth will be 
obtained from jurisdictional perinatal data collections, 
hospital separation and emergency department data. 
Such information will include complications diagnosed 
during pregnancy, episodes of care during pregnancy, 
onset of labour and the method of delivery. International 
Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision, Australian Modification 
(ICD-10-AM) codes will be used to obtain conditions from 
hospital separation and emergency department data.
Health outcomes at birth include preterm birth 
(birth <37 weeks), low birth weight (<2500 g), SGA 
(lowest 10th percentile of birth weight for gestation) and 
stillbirth (fetal death ≥20 weeks). The variables needed 
to measure these outcomes have >95% accuracy.42 Other 
available information will include date of birth, APGAR 
scores, measures of head circumference and body length, 
and days of specialised newborn care required.
Table 2 Population profile, estimated vaccine coverage and data sources, by participating jurisdiction
Western Australia Queensland Northern Territory
Population profile
  Total number of births* 208 608 375 001 23 996
  Number of births to Aboriginal 
and/or Torres Strait Islander 
women
16 748 (8.0%) 33 334 (8.9%) 8592 (35.8%)
  Median age of mothers (years) 30.6 30.1 29.0
Estimated maternal vaccine coverage†
  Influenza 31% 31% 31%
  Pertussis 17% 17% 17%
  Both vaccines 9% 9% 9%
Data sources
  Exposure
  Vaccination WA Antenatal Vaccination 
Database‡
Vaccination Information and 
Vaccination Administration 
System
NT Immunisation Register
  Outcomes
  Perinatal outcomes WA Midwives Notification 
System, WA Birth 
Registrations, WA Register of 
Developmental Anomalies
QLD Perinatal Data Collection, 
Registrar General Births
NT Perinatal Trends, NT 
Birth Registry
  Respiratory infections WA Notifiable Infectious 
Disease Database, WA 
Hospital Morbidity Data 
Collection, WA Emergency 
Department Data Collection
QLD Notifiable Conditions, QLD 
Hospital Admitted Patient Data 
Collection, QLD Emergency 
Departments
NT, Notifiable Conditions, 
NT Inpatient Activity, 
Hospital, NT Emergency, 
NT Primary Healthcare 
Collection
  Other childhood conditions WA Hospital Morbidity 
Data Collection, WA 
Emergency Department Data 
Collection, WA Register of 
Developmental Anomalies
QLD Hospital Admitted Patient 
Data Collection, Emergency 
Department Data Collection, 
Congenital Anomalies Linked 
File
NT Inpatient Activity, 
Hospital, NT Emergency, 
NT Primary Healthcare 
Collection
  Deaths WA Death Registry Registrar General Deaths NT Deaths Registry
*Estimated for the years 2012–2017; Data sources: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3301.02016?OpenDocument.
†R Andrews, personal communication based on FluMum study unpublished data, 2012–2015.
‡Data available for mothers only (no childhood immunisation data available).
NT, Northern Territory; QLD, Queensland; WA, Western Australia.
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Healthcare utilisation and severity of illness
Laboratory-confirmed influenza and pertussis infections 
in the first 6 months of life will be identified through the 
notifiable diseases databases in each jurisdiction, based 
on medical and laboratory notifications made to respec-
tive departments of health. The date of notification and 
laboratory testing result will be used to determine the 
age of the infant and gestation of mothers at the time of 
infection.
Hospital separations and emergency department data 
from each jurisdiction will be used to identify presenta-
tions and admissions to hospital for infants and children 
in the cohort. Length of stay in hospital, admission to 
ICU and requirement for mechanical ventilation will also 
be available from these records.
Access to the NT Primary Care Database will provide 
information on episodes of community clinic presenta-
tions for mothers and their children in the NT cohort, 
including reasons for and the date of the visit.
Mortality
We will use death registrations from all three jurisdictions 
to identify deaths occurring among mothers and infants 
in the cohort during the neonatal period. Death registra-
tions provide the date and cause of death for participants 
in the cohort.
Developmental anomalies: WA and QLD
Developmental anomalies will be assessed using infor-
mation in the WA Register of Developmental Anoma-
lies (WARDA) and the Congenital Anomaly Linked File 
(CALF) register in QLD. These state-wide registers main-
tain all diagnosed developmental anomalies for children 
up to the age of 5 years, using the same classification cate-
gories.43 Only the WARDA is legislated by WA state law. 
The WARDA and CALF registers include diagnostic infor-
mation for up to 10 developmental anomalies, the former 
coded using the British Paediatric Association Interna-
tional Classification of Diseases version 9 (BPA-ICD-9), 
and the latter using the ICD-10-AM coding system.
Measurement of covariates and risk factors
Information on potential confounders and factors 
required for subgroup analysis will be obtained from 
jurisdictional perinatal data collections and birth regis-
ters. These data collections include information on the 
mother’s residence at the time of delivery, which can be 
used to determine her geographical location and the 
proximity to immunisation services. The mother’s resi-
dence will also be used to determine her socioeconomic 
level based on Socioeconomic Indexes for Areas, a collec-
tion of four indices developed by the Australian Bureau 
of Statistics. For this analysis, we will use the Index of 
Relative Advantage and Disadvantage at the area level of 
collector’s district, the smallest level available for popula-
tion-wide analyses.44 The mother’s Indigenous status will 
be determined based on the Indigenous status recorded 
in all available health records. As Indigenous status is 
not always accurately captured in health data collec-
tions in WA and QLD, an algorithm developed in WA 
which uses all available health records will be applied to 
make a determination of whether the mother is likely to 
be Indigenous.45 Indigenous status is considered to be 
highly accurate (>99%) for mothers and infants in the 
NT, and is based on national best practice guidelines for 
data linkage activities relating to Aboriginal and Torres 
Strait Islander people, developed by the AIHW and meth-
odology developed in the NT for defining Indigeneity.46 
The mother’s medical history will be obtained using look-
back through hospital separations data 1 year prior to 
conception, as well as medical information recorded in 
the perinatal data collection.
record linkage
Individual information from each dataset will be linked 
using jurisdictional record linkage services. Record 
linkage uses identifiable demographic data to probabi-
listically link an individual’s clinical data from different 
data repositories. Deidentified datasets with a unique 
linkage key for each individual will be provided to the 
researchers for analysis. In WA, the Data Linkage Branch 
of the Department of Health47 will establish the study 
cohort and extract and link relevant data sources. In the 
NT, extraction and linkage will be led by SA-NT Data-
Link,48 and in QLD by the Statistical Services Branch at 
QLD Health.49
Power calculation
Cohort data will be aggregated to permit pooled, multi-ju-
risdictional analyses. We anticipate the total cohort of 
~607 605 mother-infant pairs from three jurisdictions will 
include ~208 608 pregnancies from WA, 375 001 from 
QLD and 23 996 from the NT (table 2).
The number of mother-infant pairs required for influ-
enza and pertussis-related outcomes, and adverse fetal and 
neonatal outcomes, under consideration with different 
observed vaccine coverage (for α=0.05 and β=0.80) are 
listed in table 3. Based on the anticipated total cohort size 
and expected vaccine coverage, the overall study will be 
powered to detect at least 30% effectiveness against the 
majority of infection-related end-points, with the excep-
tion of ICU admission for influenza (45%). For most safety 
end-points, the anticipated cohort size will be powered to 
detect a 10% increase in the approximated relative risk 
for vaccinated compared with unvaccinated mothers and 
infants, with the exception of stillbirth (15%) and infant 
mortality (20%) (table 3).
data analysis strategy
Using vaccination records, we will measure vaccina-
tion status and gestational timing of vaccination in the 
cohort. Among the ~607 605 women to be included in 
the study cohort, we anticipate ~30% will be vaccinated 
against influenza and <5% against pertussis during the 
2012–2015 time period; ~35% will be vaccinated against 
influenza only, ~60% against pertussis only and ~30% 
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for both vaccines from 2015 onwards.16 Three separate 
comparisons will be made: IIV-vaccinated versus unvac-
cinated, dTpa-vaccinated versus unvaccinated and IIV/
dTpa-vaccinated versus unvaccinated. Cox proportional 
hazard models will be used to approximate the relative 
risk (hazard ratio, HR) of adverse birth outcomes in vacci-
nated and unvaccinated mothers and infants. For assess-
ment of birth outcomes, these models will incorporate 
the timing of vaccination into exposure assessment in 
order to minimise immortal time bias, similar to previous 
analyses conducted.50 Gestational/post-conceptional age 
will be the time axis. The interval between vaccination 
and birth will also be included as an interaction term in 
the model.
Vaccine effectiveness of antenatal IIV and dTpa vaccines 
on laboratory-confirmed influenza and pertussis infec-
tions among mothers and their infants will be calculated 
as 1-HR. To minimise confounding in the study results, 
we plan to consider inverse probability of treatment 
weighting and propensity score matching approaches 
into analyses, where appropriate. Propensity scores will 
be calculated which will estimate each mother’s indi-
vidual probability of vaccination. Stratified models will 
be used to estimate vaccine effectiveness for sub-groups 
(ie, by trimester of vaccination, Aboriginal and/or Torres 
Strait Islander infants, preterm infants).
data management
To facilitate secure data-sharing and analysis of a pooled 
dataset across the three sites, information transfer 
between SA-NT DataLink, Curtin University, and the 
Menzies School of Health Research in Queensland will 
be facilitated through secure transfer using the SUFEX 
system using AES 128-bit encryption. Safety and secu-
rity measures are in place at these locations (restricted 
staff access, password protection, firewall, virus spyware 
protection).
Patient and public involvement
As this is a retrospective study of deidentified, linked 
data, patients cannot be involved in the design, recruit-
ment, or conduct of the study. Consumer and community 
input into the project will be regularly sought by the WA 
Healthy Pregnancies Reference Group at Curtin Univer-
sity. Research findings will be incorporated into commu-
nication materials for the community in participating 
jurisdictions.
EthICs And dIssEMInAtIon
In Australia, health legislation is state-based and 
protected by state-based privacy laws. Appropriate ethics 
committee approvals have been sought. As this research 
project involves or may impact on Aboriginal and/or 
Torres Strait Islander people, particularly in the NT, 
ethics approval has also been sought from state-based 
Aboriginal ethics committees. Approval has been granted 
from the Western Australian Department of Health 
(HREC 2016/56), Curtin University (HRE2017-0808), 
the Menzies School of Health Research (HREC 2018-
3199), and the Royal Brisbane and Women’s Hospital 
(HREC/2018/QRBW/47660) Human Research Ethics 
Committees, and the West Australian Aboriginal Health 
Ethics Committee (HREC 889). Approval from all data 
custodians has also been received.
Results will be disseminated to relevant stakeholders 
within each participating state and territory. Research 
findings will be published in peer-reviewed journals and 
presented at scientific meetings.
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Table 3 Number of mother-infant pairs required to achieve 80% power with 5% probability of type I error
Aim Outcome (estimated incidence)
Relative 
risk
Observed vaccine coverage
10% 15% 20% 25% 30%
1 Laboratory-confirmed influenza (1%) 1.30 105 370 74 827 59 975 51 472 46 216
Laboratory-confirmed pertussis infection 
(0.5%)
1.30 211 930 150 494 120 630 103 528 92 959
Hospitalised influenza (0.3%) 1.30 354 000 251 381 201 500 172 940 155 285
Hospitalised pertussis (0.4%) 1.30 265 210 188 328 150 955 129 556 116 332
Influenza-associated ICU admission (0.1%) 1.45 493 720 351 635 282 655 243 248 218 984
Pertussis-associated ICU admission (0.2%) 1.30 531 600 377 495 302 590 259 700 233 191
2 Stillbirth (0.7%) 1.15 577 410 408 802 326 725 279 624 250 384
Preterm birth (9%) 1.10 90 850 64 247 51 290 43 844 39 216
Small-for-gestational age (10%) 1.10 80 830 57 160 45 630 39 008 34 889
Birth defects (5%) 1.10 171 000 120 934 96 555 82 548 73 839
Infant mortality (0.4%) 1.20 579 100 410 415 328 340 281 272 252 101
ICU, intensive care unit.
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